{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:02:48Z","timestamp":1791223368125,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprclinrheum.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.berh.2014.10.005","type":"journal-article","created":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T18:15:00Z","timestamp":1415643300000},"page":"807-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis"],"prefix":"10.1016","volume":"28","author":[{"given":"Denis","family":"Poddubnyy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2014.10.005_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib4","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/ard.2010.145995","article-title":"Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis","volume":"70","author":"Poddubnyy","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib5","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/art.24024","article-title":"Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years","volume":"58","author":"Bennett","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/art.24483","article-title":"The early disease stage in axial spondylarthritis: results from the german spondyloarthritis inception cohort","volume":"60","author":"Rudwaleit","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.21688","article-title":"Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?","volume":"64","author":"Kiltz","year":"2012","journal-title":"Arthritis Care Res Hob"},{"key":"10.1016\/j.berh.2014.10.005_bib8","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","article-title":"Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort","volume":"65","author":"Ciurea","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/BOR.0000000000000071","article-title":"Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment","volume":"26","author":"Poddubnyy","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.005_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","article-title":"Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial","volume":"72","author":"Song","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landewe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib12","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib13","first-page":"2281","article-title":"A\u00a0new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index","volume":"21","author":"Calin","year":"1994","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.005_bib14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/annrheumdis-2012-203055","article-title":"Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial","volume":"73","author":"Haibel","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib20","first-page":"10","article-title":"Are classification criteria for spondylarthropathy useful as diagnostic criteria?","volume":"62","author":"Amor","year":"1995","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.berh.2014.10.005_bib21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","article-title":"Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis\u2013a population-based survey","volume":"25","author":"Zochling","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.005_bib22","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib25","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib26","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib27","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib29","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.005_bib31","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib32","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial","volume":"71","author":"Song","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.berh.2014.10.005_bib34","article-title":"Long-term safety and efficacy of certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 96-week outcomes of the RAPID-axSpA trial","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2014.10.005_bib35","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"The symptomatic efficacy and effect on objective signs of inflammation of etanercept in early nonradiographic axial spondyloarthritis","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2014.10.005_bib36","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","article-title":"Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study","volume":"41","author":"Breban","year":"2002","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2014.10.005_bib37","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.005_bib38","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.005_bib39","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2014.10.005_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","article-title":"Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST part 2","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14712598.2014.868433","article-title":"Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients","volume":"14","author":"Borras-Blasco","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.berh.2014.10.005_bib42","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2014.10.005_bib43","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib44","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib45","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/annrheumdis-2012-202245","article-title":"Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis","volume":"72","author":"Paramarta","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2014.10.005_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.38.Suppl_1.32","article-title":"Reiter's syndrome: long-term follow-up data","volume":"38","author":"Amor","year":"1979","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.56.1.32","article-title":"Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial","volume":"56","author":"Egsmose","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib48","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3899\/jrheum.121192","article-title":"Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis","volume":"40","author":"Barber","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.005_bib49","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/acr.21940","article-title":"Factors associated with attrition in a longitudinal rheumatoid arthritis registry","volume":"65","author":"Iannaccone","year":"2013","journal-title":"Arthritis Care Res Hob"},{"issue":"Suppl. 2","key":"10.1016\/j.berh.2014.10.005_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF02203389","article-title":"Natural course and prognosis of HLA-B27-positive oligoarthritis","volume":"6","author":"Schattenkirchner","year":"1987","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.005_bib51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jama.1966.03110200049016","article-title":"An \u201cexperimental\u201d epidemic of Reiter's syndrome","volume":"198","author":"Noer","year":"1966","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.berh.2014.10.005_bib52","doi-asserted-by":"crossref","first-page":"564","DOI":"10.7326\/0003-4819-84-5-564","article-title":"An \u201cexperimental\u201d epidemic of Reiter's syndrome revisited. Follow-up evidence on genetic and environmental factors","volume":"84","author":"Calin","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2014.10.005_bib53","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/ard.56.9.516","article-title":"Long-term prognosis of reactive salmonella arthritis","volume":"56","author":"Leirisalo-Repo","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.005_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0002-9343(99)80076-X","article-title":"Post-Salmonella reactive arthritis: late clinical sequelae in a point source cohort","volume":"98","author":"Thomson","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2014.10.005_bib55","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s10067-013-2247-x","article-title":"Outcome of reactive arthritis after an extensive finnish waterborne gastroenteritis outbreak: a 1-year prospective follow-up study","volume":"32","author":"Uotila","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.005_bib56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s100670170066","article-title":"Undifferentiated spondyloarthropathies: a 2-year follow-up study","volume":"20","author":"Sampaio-Barros","year":"2001","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.005_bib57","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3899\/jrheum.090625","article-title":"Undifferentiated spondyloarthritis: a longterm followup","volume":"37","author":"Sampaio-Barros","year":"2010","journal-title":"J\u00a0Rheumatol"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694214000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694214000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T21:55:33Z","timestamp":1538085333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694214000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1521694214000874"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2014.10.005","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2014.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}